The scrutiny follows the company’s May 7, 2026, financial report, which revealed a $3.13 billion revenue figure for the fourth quarter—a 6.6% decline on an organic basis. Management admitted during an earnings call that they missed organic revenue guidance by approximately $75 million, attributing the failure to both market demand shifts and internal operational shortcomings. Bookings also suffered, falling 13.5% year over year to $3.3 billion.

Investors reacted sharply to the disclosure, driving shares down $2.58 to close at $9.43 on May 8. With the company projecting a further organic revenue decline of 3% to 5% for fiscal year 2027, Pomerantz LLP is now evaluating whether officers or directors violated securities laws. Those holding DXC stock are being directed to contact Danielle Peyton at the firm to discuss potential class action participation.